Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 17OTHER 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1

Interventions

Cyclophosphamide 12Rituximab 9fludarabine 6Prednisone 5Vinorelbine 4Vincristine 4Epirubicin 4zanubrutinib 3Nivolumab 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Gemcitabine 3Drug Therapy 3pegylated granulocyte colony-stimulating factor 2fludarabine phosphate 2Thiotepa 2Metformin 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Doxorubicin 2Cytarabine 2Bortezomib 2treosulfan 1plerixafor 1pegfilgrastim 1parsaclisib 1obinutuzumab 1nilotinib 1liposomal doxorubicin 1ivarmacitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × parsaclisib × Lymphoid × Clear all
NCT05083208 2025-12-02

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Henan Cancer Hospital

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡